Drug Channels
Pages
(Move to ...)
ABOUT
INDUSTRY REPORTS
WEBINARS
KEYNOTE SPEAKING
ADVERTISE
SUBSCRIBE / CONTACT
▼
Friday, April 19, 2024
How GoodRx is Evolving Its Reimbursement Approaches to Help Pharmacies and Consumers
›
Today’s guest post comes from Jim Sheninger, Pharmacy Strategy Officer at GoodRx. Jim describes GoodRx's emerging pharmacy contracting...
Tuesday, April 16, 2024
The Top 15 Specialty Pharmacies of 2023: Market Shares and Revenues at the Biggest PBMs, Health Plans, and Independents
›
Drug Channels Institute’s (DCI’s) latest analysis finds that participants in the specialty pharmacy market continue to get more diverse—alth...
Friday, April 12, 2024
How Patient Engagement Can Reduce Brand Launch Risks
›
Today’s guest post comes from Jessica Lens, Chief Patient Experience Officer at CareMetx. Jessica discusses the challenges of patient non...
Tuesday, April 09, 2024
The Top Pharmacy Benefit Managers of 2023: Market Share and Trends for the Biggest Companies—And What’s Ahead
›
Three is still the magic number for pharmacy benefit managers (PBMs). For 2023, nearly 80% of all equivalent prescription claims were proce...
Monday, April 08, 2024
SAVE THE DATE: Drug Channels Leadership Forum, March 17-19, 2025
›
I am pleased to announce the inaugural Drug Channels Leadership Forum ! This unique, new event will be held from March 17 to 19, 2025, at th...
Friday, April 05, 2024
Tales of the Unsurprised: U.S. Brand-Name Drug Prices Fell for an Unprecedented Sixth Consecutive Year—And Will Fall Further in 2024 (rerun)
›
This week, I’m rerunning some popular posts while I prepare for today’s live video webinar: Drug Channel Implications of the Inflation Reduc...
Thursday, April 04, 2024
Vertical Integration Lessons: The Economics and Strategies of Hospital-Owned Specialty Pharmacies (rerun)
›
This week, I’m rerunning some popular posts while I prepare for tomorrow’s live video webinar: Drug Channel Implications of the Inflation Re...
Wednesday, April 03, 2024
The Big Three PBMs’ 2024 Formulary Exclusions: Biosimilar Humira Battles, CVS Health’s Weird Strategy, and the Insulin Shakeup (rerun)
›
This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: Drug Channel Implications of the Inflation Redu...
Tuesday, April 02, 2024
What CVS Pharmacy’s New Cost-Plus Reimbursement Approach Means for PBMs, Pharmacies, Plan Sponsors, and Prescription Prices (rerun)
›
This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: Drug Channel Implications of the Inflation Redu...
Monday, April 01, 2024
Understanding CVS Health/McKesson and Why Pharmacies Lose Money on GLP-1s (rerun)
›
This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: Drug Channel Implications of the Inflation Redu...
Thursday, March 28, 2024
Navigating Market Access Challenges in Life Sciences Commercialization
›
Today’s guest post comes from Bill Dupere, SVP of Product Development & Partnerships at Mercalis. Bill discusses specialty therapy acc...
Tuesday, March 26, 2024
Drug Channels News Roundup, March 2024: My $0.02 of CarelonRx/Kroger & CVS, Provider-Owned Pharmacies, Shady AFPs, 340B Deception, and Lilly’s GLP-1 Ad
›
It’s finally spring in Philadelphia, home of Drug Channels . Along with sunshine and fine weather, the vernal equinox has ushered in a crop ...
›
Home
View web version